Materials and Methods: In-111-DOTA-trastuzumab Protein Tyrosine Kinase inhibitor was prepared followed by determination of radiochemical purity (RCP), integrity of protein, immunoreactivity of radiolabeled antibody with HER2/neu antigen (by SkBr3 cell line binding and RIA methods)

were determined followed by stability tests, internalization studies and the tissue bio-distribution determination in wild-type rats as well as SPECT imaging in SkBr3-bearing mice. Statistical Analysis Used: All values were expressed as mean +/- standard deviation (mean +/- SD) and the data were compared using Student’s t-test. Statistical significance was defined as P smaller than 0.05. Results: In-111-DOTA-trastuzumab was prepared (RCP bigger than 95 +/- 0.5%, S. A. 5.3 mu Ci/mu g) with the average number of chelators

per antibody of 6: 1 showing significant immune-reactivity retention using ELISA. In vitro stability was bigger than 90% in phosphate buffered saline and 80 +/- 0.5% in serum over 48 h. Cell binding was significant ( bigger than 0.79). In vitro internalization reached up to %12-13 in 10 h. Significant tumor uptake was observed. Conclusions: In vitro and in vivo/SPECT imaging in SkBr3-bearing mice demonstrated that In-111-DOTA-trastuzumab is a potential compound for molecular imaging of SPECT for diagnosis and follow-up of HER2 expression in oncology.”
“Obesity is a major health problem. We investigated the effects of forskolin and rolipram in the diet of animals in which obesity had been induced. We used 50 female albino Wistar rats

that were assigned randomly into five groups as follows: group 1, control; KU-57788 research buy group Cell Cycle inhibitor 2, high fat diet; group 3, high fat diet + forskolin; group 4, high fat diet + rolipram; and group 5, high fat diet + rolipram + forskolin. The rats were fed for 10 weeks and rolipram and forskolin were administered during last two weeks. The animals were sacrificed and blood samples were obtained. Serum cAMP, cGMP and free fatty acids (FFA) levels were measured using ELISA assays. We also measured weight gain during the 10 week period. cAMP and FFA levels of groups 3, 4 and 5 were significantly higher than those of groups 1 and 2. We found no significant differences in serum cGMP levels among the groups. The weight gain in groups 3, 4 and 5 was significantly less than for group 2. We also found that the weight gain in group 5 was significantly less than in groups 3 and 4. We found that both forskolin and rolipram stimulated lipolysis and inhibited body weight increase by increasing cAMP levels. Also, combination therapy using the two agents may be more effective in preventing diet induced obesity than either agent alone. We found also that these agents did not effect cellular cGMP levels in diet induced obesity.”
“To evaluate the impact of iterative reconstruction on the detectability of clots.